Direct neuronal reprogramming from various cell sources has developed into a very active field since its beginning in 2002^1^ using either neurogenic transcription factors or small molecules or a combination thereof (for recent review see ref. 2). Among the small molecules Forskolin (Fk) stands out as it was previously shown to facilitate reprogramming in different models of trans-differentiation *in vitro*,[@cit0003] including direct neuronal reprogramming.[@cit0006] Accordingly, Fk is also an invariable component of the neuronal reprogramming cocktails based on small molecules.[@cit0007] We recently found that both Fk treatment and Bcl-2 expression exert a similar effect in increasing reprogramming efficiency mediated by single transcription factors and in reducing oxidative stress, a key limiting factor in direct neuronal reprogramming.[@cit0010] In fact, they both potently enhance the rate of conversion and survival during neuronal reprogramming mediated by single transcription factors,[@cit0010] regardless of the cell type of origin (astrocytes, fibroblasts; see refs. 6 and 10), species (human, mouse, gerbil; see refs. 6--10 and data not shown) and transcription factor (Ascl1, Neurog2, NeuroD4; see refs. 6, 10 and data not shown). While these results showed a similar potency of Fk and Bcl-2 in direct neuronal reprogramming, genome-wide expression analysis further highlighted shared down-stream effector pathways such as RXR/VDR and Nrf2,[@cit0010] prompting the question of how these transcriptional effectors are activated.

Fk is well known to activate the cyclic AMP-response element-binding protein (CREB)[@cit0011] which is induced by the protein kinase A (PKA) and, as expected, was also increased in the above described transcriptome of Fk effectors.[@cit0010] Moreover, CREB has been related to cellular processes that are essential for the normal maintenance of brain function, such as memory formation,[@cit0012] synaptic plasticity,[@cit0014] adult neurogenesis,[@cit0016] and neuronal differentiation of stem cells.[@cit0019] Additionally, it has been described that CREB participates in the metabolic regulation of neurogenesis,[@cit0020] a function that may facilitate the neuronal metabolic conversion during neuronal direct reprogramming.[@cit0010] CREB also boosts cell survival,[@cit0021] by activating transcription of genes such as *Brain-Derived Neurotrophic Factor* (BDNF)[@cit0023] and *Bcl-2*[@cit0024] further supporting a possible link between the effects of Fk, CREB and Bcl-2 in reprogramming. Therefore we aimed here to determine the role of CREB-mediated transcription in neuronal reprogramming. Importantly, CREB is a crucial upstream regulator of the immediate early genes (IEG)[@cit0025] and, hence, its activation occurs fast, transiently and does not require de novo protein synthesis. Hence, we modulated CREB activity permanently and transiently to address when and for how long CREB activity may be needed during reprogramming.

As a first step to analyze if and when CREB may mediate the effect of Fk in neuronal reprogramming we examined the dynamics of CREB phosphorylation in astrocytes transfected with *Ascl1*-IRES-*DsRed* plasmids and stained for P-CREB, β-III-tubulin and DsRed at different time points after Fk addition at one day post-transfection (DPT) ([Fig. 1A, B](#f0001){ref-type="fig"}). Phosphorylation of CREB was induced in most cells 1 h after addition of Fk, independent of whether they were immuno-reactive for DsRed (Ascl1-positive; [Fig. 1A and B](#f0001){ref-type="fig"}) or not (Ascl1-negative; [Fig. 1A, upper panels](#f0001){ref-type="fig"}). Interestingly, at yet later time points, 24 h to 72 h without Fk addition, P-CREB-immunoreactivity was higher in transfected DsRed+ cells, ([Fig. 1A, left columns](#f0001){ref-type="fig"}, and [Fig. 1B](#f0001){ref-type="fig"}) suggesting that *Ascl1* potentiates or prolongs CREB phosphorylation. At 24 to 72 h of treatment with Fk, P-CREB-immunoreactivity was reduced in DsRed positive cells when compared with cultures lacking Fk([Fig. 1A, right columns](#f0001){ref-type="fig"}, and [Fig. 1B](#f0001){ref-type="fig"}). These data indicate that exposition of astrocytes to Fk induces a short phosphorylation of CREB followed by a long dephosphorylation during reprogramming. Western blot analysis upon adding Fk for different periods of time to the astrocyte cultures showed that P-CREB and its homolog cAMP-responsive element modulator (CREM) were increased in cells treated with Fk for 30 min and 2 h, while longer periods of treatment (\> 7h) decreased P-CREB/CREM below basal levels ([Fig. 1C](#f0001){ref-type="fig"}). In contrast, total levels of CREB protein were not affected by the treatment, ruling out effects via protein degradation or transcription ([Fig. 1C](#f0001){ref-type="fig"}). Interestingly, PKA activity also increases transiently as monitored by labeling for its targets with phosphorylation at Ser/Thr residues (peak at 2 hours after Fk; see [Fig. 1C](#f0001){ref-type="fig"}), but levels did not decline below baseline upon prolonged Fk exposure as observed for P-CREB ([Fig. 1C](#f0001){ref-type="fig"}). Hence, among PKA substrates only CREB phosphorylation was observed to be specifically reduced upon long periods of treatment with Fk (\> 24 h). This interesting pattern of activity was similar in other cell types exposed to Fk for different lengths of time such as MEFs and neurosphere-derived cells (Supp. Figure 1) suggesting a feed-back mechanism inactivating CREB phosphorylation upon prolonged Fk exposure in many cell types. Although peculiar, this behavior is not surprising for a master regulator of IEGs.[@cit0025] Figure 1.Fk induces a fast transient phosphorylation followed by a persistent de-phosphorylation of CREB. (A) Micrographs of astroglial cultures transfected with the *Ascl1*/*DsRed*-encoding vector and treated 24 h later with Fk (20 μM, right panels) or maintained untreated (left panels). High magnification pictures (upper panels) show the expression of DsRed (Red; white arrows depict transfected cells), β-III-tubulin (green) and P-CREB (see white in splitted channels) by immunostaining at different time points after Fk was supplemented. Low magnification fields in the lower panels show the expression of DsRed (Red) and P-CREB (green) at the 24 h time point. (B) Quantification of cells depicted in (A) shows the percentage of astrocytes immunoreactive for P-CREB among cells transfected with *Ascl1* and maintained untreated (white bars) or treated with Fk (black bars) and untransfected cells maintained untreated (gray bars). (C) Radiographs show P-CREB, total CREB, PKA substrate and α-tubulin detected in un-transfected astroglia cultures by immunobloting of western blots with specific antibodies. On the left lysates from postnatal astroglia cultures incubated with Fk (20μM) for 2 h, 7 h, 24 h or maintained untreated. On the right cultures were maintained untreated or treated with Fk for the first 7 h or during the entire duration of the experiment (48 h). (D) Histogram shows fold increase of β-III-tubulin immunopositive neurons among *Ascl1*/*DsRed* transfected astroglial cells in vitro when 24 h later were treated with Fk only during the first 7 h or during the entire duration of the experiment (7 days). Scale bars represent 40 µm. Error bars indicate ± SD. \*p\<0.05, \*\*p\<0.01; ANOVA with Tukey\'s post hoc test.

If the hypothesis that CREB mediates the effect of Fk on neuronal reprogramming is correct, we have to consider 3 different options: a) The short activation of CREB is enough to enhance reprogramming b) Persistent reduction of CREB activity is beneficial for reprogramming rather than its activation c) Increase in reprogramming requires the dynamic behavior of transient short CREB phosphorylation followed by persistent dephosphorylation. To address the options a and b, astroglial cultures were transfected as before with *Ascl1*/*DsRed* encoding plasmids and 24 h later, the cultures were maintained untreated or treated with Fk for 7 h or for the entire duration of the experiment. The cells were fixed 48 h or 5 d later and the levels of P-CREB, CREB and PKA (see WB in the [Fig. 1C](#f0001){ref-type="fig"}, right panels) and reprogramming efficiency ([Fig. 1D](#f0001){ref-type="fig"}) was analyzed respectively. We observed that reduction of P-CREB levels required a persistent treatment with Fk ([Fig. 1C, right panels](#f0001){ref-type="fig"}). Moreover, while short treatment with Fk faintly increased reprogramming efficiency, only prolonged exposure to Fk resulted in doubling of neuronal reprogramming efficiencies ([Fig. 1D](#f0001){ref-type="fig"}). These data together suggest that the long-term Fk treatment and, hence, the long-term decrease in P-CREB levels may be beneficial for reprogramming.

If the above hypothesis is correct, a maintained CREB-mediated transcription should interfere with reprogramming. To test this prediction, we used the dominant positive CREB-VP16 fusion protein, which constitutively activates transcription of cAMP response elements (CRE) through the transcriptional activation domain of the herpes virus VP16 protein.[@cit0026] Astrocyte cultures were co-transfected with the *Ascl1-DsRed* and CREB-VP16 or control vector plasmids, treated or not with Fk and neuronal reprogramming was examined at 1, 6 or 12 DPT ([Fig. 2](#f0002){ref-type="fig"}). The beneficial effect of Fk was already visible in cells transduced only with Ascl1 at 6 DPT with 20% into β-III-tubulin+/GFAP- neurons without Fk and 40% with Fk ([Fig. 2C](#f0002){ref-type="fig"}). Neuronal conversion continued to increase in both conditions, but the cells cultured with Fk had generated significantly more neurons (over 90%) than those without (around 75%). In contrast, when Ascl1 and CREB-VP16 were co-transduced only 20% neurons were detectable at 12 DPT ([Fig. 2C](#f0002){ref-type="fig"}). Interestingly, cells co-transfected with CREB-VP16 were immunoreactive for β-III-tubulin but neither had neuronal morphology nor managed to turn off glial hallmarks such as GFAP ([Fig. 2A, B](#f0002){ref-type="fig"}). Thus, CREB-VP16 blocks astrocyte conversion to neurons. As expected, Fk addition or not made no difference any longer when cells were co-transduced with Ascl1 and CREB-VP16 ([Fig. 2C, D](#f0002){ref-type="fig"}). Conversely, CREB-VP16 co-transduction increased the total number of cells suggesting that it increases survival of the cells which do not successfully reprogram and normally die ([Fig. 2E](#f0002){ref-type="fig"}), thereby separating the effect of Fk treatment on reprogramming from effects on cell survival. Figure 2.Expression of constitutive activated CREB recombinant protein or the natural dominant negative ICER both reduce neuronal conversion of astrocytes. (A) Micrographs show expression of β-III-tubulin (green) in astroglial cultures transfected with the *Ascl1*/*DsRed*-encoding plasmid alone (red cells; left panel) or in combination with the CREB-VP16-encoding plasmid (red cells; right panel) at 6 DPT. Note that cells co-expressing Ascl1/*DsRed* and CREB-VP16 are immunopositive for β-III-tubulin, but do not acquire neuronal morphology. (1) Higher magnification of the above cells shows that cells transfected with the *Ascl1/DsRed*-encoding plasmid (arrows; left column) acquire neuronal morphology (red; upper panel), induced expression of β-III-tubulin (green; middle panel) and down-regulate the astrocytic hallmark GFAP (blue; lower panel). Co-expression of Ascl1/DsRed and CREB-VP16 (arrows; right column) induces expression of β-III-tubulin (green; middle panel) in astrocytes but the cells neither acquire neuronal processes (red; upper panel) nor switch off GFAP expression (blue; lower panel). (C-E) Graphs show cell fate outcome at different time points (6 and 12 DPT) of postnatal astroglial cultures transfected with plasmids encoding *Ascl1-DsRed, Ascl1-DsRed*+*CREB-VP16* or *Ascl1-DsRed*+*Icer*, that were maintained untreated or incubated with Fk (20 μM) for the duration of the experiment. Quantifications show the percentage of neurons (β-III-tubulin+/GFAP-) among the total number of DsRed immunopositive cells (C) and the absolute number neurons (D) or total number of cells (E) immunoreactive for DsRed and normalized by the number of transfected cells at 1DPT. Scale bars represent 100 µm in (A) and 50 µm in (B). Error bars indicate ± SD. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001; ANOVA with Tukey\'s post hoc test.

Since Fk induces P-CREB by increasing PKA activity, we next analyzed whether this enzyme may have a positive effect on reprogramming. We transfected astroglial cultures with the plasmid encoding *Ascl1*/*DsRed*, in combination with a second plasmid encoding either the catalytic subunit-α of PKA (PKAα) or a control plasmid. Constitutive expression of PKAα also dramatically reduced reprogramming in astroglial cells. When cells were examined at 7 DPT we observed a 20x reduction in the induced neurons, from 44% neurons among the *Ascl1*-only transduced cells to less than 2% among *Ascl1* and *PKA* transduced cells (Supp. Figure 2). Thus, similarly to the effect of CREB-VP16, PKA co-transduction also resulted in a reduction of reprogrammed neurons.

Considering these results, we next assessed whether a reduction of CREB-mediated transcription has the opposite effect and enhances reprogramming. To test this, we co-transfected astroglial cells with vectors encoding *Ascl1*/*DsRed* and the inducible cAMP early repressor (ICER), which is a natural dominant negative form of CREB.[@cit0027] Interestingly, ICER co-expression dramatically reduced survival of cells during reprogramming with only 20% left after 12 DPT ([Fig. 2E](#f0002){ref-type="fig"}). While the proportion of induced neurons was lower than the control transfected with Ascl1 only at 12 DPT (∼55% +ICER; ∼75% -ICER; [Fig. 2C](#f0002){ref-type="fig"}), but still higher than upon Ascl1 and CREB-VP16 co-transduction (around 15%). However, when considering the death of cells and quantifying the total number of neurons this was lowest for cells co-transduced with Ascl1 and ICER at 12 DPT ([Fig. 2D](#f0002){ref-type="fig"}). Taken together, these data indicate that constant levels of increased CREB-mediated transcription increases cell survival while constant block of CREB by ICER decreases survival. Conversion into neurons, however was worse than the control for both cases as well as PKA co-transduction. These results thus suggest that the dynamic regulation with first increased and later decreased levels of P-CREB (see option **c** above) may be the key to improve the efficiency of neuronal conversion of astrocytes.

To test this hypothesis we designed a vector, TREp-CREB-VP16 ([Fig. 3A](#f0003){ref-type="fig"}), based on the Tet-On system in which the cDNA encoding *CREB-VP16* protein is driven by the tetracycline response element (TRE), that induces transcription of *CREB-VP16* only in presence of doxycycline (DOX) and the reverse tetracycline-controlled transactivator (rtTA). Astroglial cells were co-transfected with the plasmids encoding *Ascl1*/*DsRed* and *rtTA* alone or in combination with the vector TREp-CREB-VP16. Twenty-four hours after transfection, the expression of CREB-VP16 was briefly induced by addition of DOX in the differentiation medium during a period of 5 h and the cells were maintained without DOX until the end of the experiment. In a separate series of experiments, the plasmid encoding ICER was also included in the transfection together with TREp-CREB-VP16 and *Ascl1*/*DsRed* and *rtTA* coding plasmids (ratio 3:1 respectively for the *CREB-VP16:ICER* encoding plasmids) to accelerate the reduction of CREB-VP16 activity after treatment with DOX ([Fig. 3A](#f0003){ref-type="fig"}). We observed that transient expression of CREB-VP16 significantly increases cell viability at 6 as well as 12 DPT ([Fig. 3B](#f0003){ref-type="fig"}). However, most of the cells were not successfully reprogrammed into neurons ([Fig. 3C](#f0003){ref-type="fig"}) as they were immuno-positive for both, β-III-tubulin and GFAP and did not acquire neuronal morphology ([Fig. 3D, left panels](#f0003){ref-type="fig"}). On the contrary, cells co-transfected with the vector TREp-CREB-VP16 and the plasmid encoding *ICER* successfully reduced GFAP expression ([Fig. 3D, right panels](#f0003){ref-type="fig"}) and acquired neuronal morphology along of the time in culture ([Fig. 3E](#f0003){ref-type="fig"}). Indeed, transient expression of CREB-VP16 in combination with stable expression of ICER increased both, cell survival (1,7 ± 0.12 x compared with *Ascl1* only expressing cells at 6 d after transfection; [Fig. 3B](#f0003){ref-type="fig"}) and total number of neurons (1,87 ± 0.2 and 2,12 ± 0.15 x compared with Ascl1 expressing cells respectively at 6 and 12 DPT; [Fig. 3C](#f0003){ref-type="fig"}). Thus, the efficient and fast shut off of P-CREB is essential for reprogramming, while initial activation is essential for survival. These results thus clearly demonstrate that a short "on-off" switch of CREB activity improves Ascl1-mediated conversion of postnatal astroglial cells. Figure 3.Transient activation of CREB allows to increase conversion of postnatal astrocytes into iNs. (A) Scheme of the vectors used to transiently induce transcription mediated by CREB: the expression of CREB-VP16 is driven by the inducible promoter TRE which is transcriptionally active only in the presence of the coactivator rtTA and DOX. (B, C) Graphs show the outcome of cells co-transfected with the indicated combination of plasmids 20--30 h after plating. At 1 DPT, cultures were incubated with DOX for a period of time of 5 h, and then left untreated for 6 or 12 d in culture. Quantifications show the percentage of transfected cells (DsRed+) classified as neurons (β-III-tubulin+/GFAP-) normalized to the number of transfected cells at 1 DPT (B) and the absolute number of cells immunoreactive for DsRed also normalized to the number of transfected cells at 1 DPT (C). (D) Micrographs show cells immunoreactive for DsRed (upper panels; blue arrows) which were transfected with the combination of plasmids *Ascl1-DsRed*/transient *CREB-VP16* (left column) or *Ascl1-DsRed*/transient *CREB-VP16*/*Icer* (right column). The neuronal outcome was analyzed by immunostaining (lower panels) for β-III-tubulin (green) and GFAP (red). Note that only cells co-expressing *Icer* upregulated β-III-tubulin, switched off GFAP expression and exhibited a complex neuronal morphology. (E), Still images from video-time lapse show a cell transfected (DsRed expression in white) with *Ascl1-DsRed*, transient *CREB-VP16* and *Icer* acquiring neuronal morphology along of 7 d in culture. Scale bars represent 50 µm. Error bars indicate ± SD. \*p\<0.05, \*\*p\<0.01; ANOVA with Tukey\'s post hoc test.

As mentioned above, *Bcl-2* is a known direct target of CREB. Since the expression of Bcl-2 enhances survival and conversion efficiency during neuronal reprogramming similarly as Fk does,[@cit0010] we hypothesized that Fk treatment and CREB-transient activity may partially mediate its beneficial effect in reprogramming by rising endogenous levels of Bcl-2. Indeed, treatment of astrocytes and fibroblasts with Fk caused the progressive accumulation of Bcl-2 protein, as detected by Western Blot (Supp. Figure 3A, B). Moreover, postnatal astrocytes co-transfected with *Ascl1*/*DsRed* and *CREB-VP16* encoding plasmids exhibited a higher immunoreactivity for Bcl-2 compared with only *Ascl1*/*DsRed* transfected controls (Supp. Figure 3C), demonstrating that CREB-activity increases Bcl-2 protein levels during reprogramming. These results strongly suggest that the effect of Fk and CREB activation in reprogramming may be mediated by Bcl-2, at least, partially.

In summary, our work provides direct evidence that transcription mediated by CREB is beneficial for direct neuronal reprogramming. However, this pathway must be tightly regulated to allow an optimal efficient conversion. We demonstrated here that CREB-mediated transcription always correlates to an increase of cells surviving to reprogramming, however, either persistent blockage or persistent boost of CREB activity result in a reduction in the number of neurons derived from astrocytes. Previous results in mouse models of adult neurogenesis in the hippocampus also highlighted the importance of a precise control of CREB activity for the expansion and differentiation of neuronal progenitors. Thus, a potent reduction of CREB activity mediated by a dominant-negative form of CREB exhibited reduced proliferation of neuronal progenitors in the adult hippocampus[@cit0016] while a mild reduction in CREB deficient mice (CREB^αΔ^) that preserve the homologous gene *CREM* showed increased proliferation and concomitant neuronal differentiation of progenitors.[@cit0028] These results indicate that CREB-mediated transcription can also lead to opposite effects on neuronal precursors *in vivo* and, therefore, suggest that its activation has to be precisely controlled during natural neurogenesis as well. Moreover, the dramatic effect of CREB-VP16 impeding the acquisition of neuronal features in our model of astrocyte-to-neuron conversion is not completely unexpected considering that CREB can activate a plethora of non-neuronal genes[@cit0029] that may interfere with a successful neurogenesis program. Therefore, all together, previous data *in vivo*, the results of this study and the nature of CREB as fast transient effector regulating IEG pathways suggest that short temporal activation of CREB is most likely the correct road to improve neurogenesis in both natural differentiation and forced reprogramming paradigms.

As mentioned above, besides the effect of CREB-transcription on neuronal reprogramming, CREB protein targets a vast number of genes that are not necessarily linked to a neuronal identity (∼1350 genes in mouse and ∼1663 in the human; see ref. 29). Consequently, Fk also activates molecular cascades that are involved in many different cellular contexts.[@cit0010] These data suggest that CREB and Fk may also play roles in other non-neuronal reprogramming paradigms. Supporting this, it has been shown that Fk treatment allows trans-differentiation of bone marrow-derived neurons into epithelial cells.[@cit0004] Therefore, it will be interesting to explore the extent to which Fk and transient activation of CREB may contribute to direct reprogramming of somatic cells into non-neuronal lineages such as, for example, cardiomyocytes,[@cit0030] endocrine pancreatic β cells[@cit0031] and glial cells.[@cit0032] Finally, the results of our previous study showing a beneficial of Bcl-2 in direct neuronal reprogramming[@cit0010] as well as the results of this study confirming that both Fk treatment and CREB-mediated transcription induce Bcl-2 protein levels, strongly suggest that Bcl-2 may be a crucial mediator of the effect of Fk in cell fate re-specification of different lineages by molecular cues that are not completely elucidated yet.

Methods and materials {#s0002}
=====================

Cell cultures of astroglia from the postnatal mouse cerebral cortex {#s0002-0001}
-------------------------------------------------------------------

Astrocytes were cultured as described in Heins *et al.* (2002). After removal of the meninges, gray matter tissue was dissected from P5-P7 cerebral cortex of C57BL/6J mice and dissociated mechanically. Subsequently, cells were centrifuged for 5 min at 1000 rpm, re-suspended, and plated in medium consisting of DMEM/F12 (Gibco), 3.5 mM glucose (Sigma), 10% fetal calf serum (Gibco), 5% horse serum (Gibco), penicillin/streptomycin (Gibco) and supplemented with B27 (Gibco), 10 ng/mL epidermal growth factor (EGF, Roche) and 10 ng/mL fibroblast growth factor 2 (FGF2, Roche). After one week expansion cells were harvested using trypsin/EDTA (Gibco) and plated onto poly-D-lysine (Sigma-Aldrich) coated glass coverslips in 24-well plates (BD Biosciences) or directly onto plastic for time lapse experiments at a density of 60,000 cells per well in the same medium.

Transfection of mouse postnatal astroglia cultures {#s0002-0002}
--------------------------------------------------

Cells were transfected always 24 h after plating. For transfection DNA-liposome complexes were prepared in Optimem medium (Invitrogen) using the retroviral plasmids described below and Lipofectamine 2000 (Invitrogen). Astrocyte cultures were exposed to DNA-liposome complexes at a concentration of 0.5 µg DNA per 400 µl of Optimem medium for 4 hours and cultured after that in the differentiation medium as above. (See ref. 33). For survival analysis of transfected cells after immunostaining we counted the total number of DsRed+ cells at 5 DPT and normalized by the total number of DsRed+ cells counted at day 1. To quantify the ratio of neurons/initial transfected cells the proportion of DsRed+/β-III-tubulin+ cells was assessed at 5 DPT and normalized to the population of DsRed+ cells at 1 DPT.

Cell cultures of mouse embryonic fibroblasts (MEFs) {#s0002-0003}
---------------------------------------------------

MEFs were obtained from mouse embryos at day 14 gestation. Head, spine and visceras were removed and discarded.[@cit0034] The remaining tissue was dissociated with 0.15% of trypsin, centrifuged for 5 min at 1300 rpm, re-suspended, and plated in a medium consisting of DMEM high glucose (3.5mM) with GlutaMAX (Gibco), 10% fetal calf serum (Gibco) and penicillin/streptomycin (Gibco) in 5% CO2 and normoxygenated conditions. Fibroblasts were used for experiments after minimum 3 passages. For reprogramming experiments cells were harvested and replated as described above for astrocytes.

Neurosphere cultures {#s0002-0004}
--------------------

For culturing neurosphere cells from postnatal cerebral cortex we followed the protocol described by Johansson et al. (1999). After 5--7 d in culture, neurosphere cells were enzymatically dissociated with trypsin (Invitrogen) and plated on poly-D-lysine (Sigma-Aldrich) coated coverslips at a density of 10 × 10^4^ cells per coverslip (in 24-well plates, BD Biosciences) in a medium consisting of DMEM/F12 supplemented with B27, EGF, FGF2, penicillin/streptomycin, and buffered with HEPES (i.e. neurosphere medium).
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